CellCentric has a unique approach to harnessing innovation through a platform of multiple relationships with worldwide leaders in epigenetics. The strength of the company’s model and the value created to the multiple stakeholders involved, is reviewed in a new publication.
CAMBRIDGE, UK, 28th August 2009
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has built a discovery platform based on exclusive relationships with multiple research leaders in epigenetics. The company’s novel approach to translating emerging science into commercial development is reviewed in the latest edition of Cell’s Trends in Biotechnology (now available online).
Organizing for innovation: towards successful translational research.
West W & Nightingale P, Trends Biotechnol., Aug 2009 (EPub ahead of print).
The benefits of CellCentric’s novel approach are outlined in the article. These include the ability to adapt to the ever increasing complexity of identifying and translating relevant research in an emerging and fragmented scientific field. CellCentric is able to piece together early data ahead of competition, and has a greater ability to contextualise new findings from multiple labs. The relevance of this new model to the healthcare sector is explored, as well as the value to all stakeholders, including Technology Transfer Organisations, Institutions, research funders, the scientists themselves and customers of the product opportunities identified and developed.
CellCentric has used its model successfully to focus in on 7 novel target programmes, multiple new research tool technologies and some screening activity in cellular reprogramming.
For further information contact:
CellCentric
Will West Tel: + 44 (0) 1799 531 130
Epigenetics
Epigenetics concerns the processes that help govern chromatin structure and function, by which cell fate is controlled. This is an emerging field that is leading to a series of novel approaches to intractable diseases, including cancer. DNA demethylases and histone deacetylases (HDACs) have pioneered the therapeutic potential of the space, but it is clear that there are many other rational targets associated with epigenetics that could have real clinical impact.
About CellCentric
CellCentric’s business model and strategy is designed to ensure that it has the best chance of success in delivering the next wave of epigenetic targets and product candidates.
Currently CellCentric is running small molecule discovery programmes on 7 novel targets that have been prioritised from a wide pool of candidates identified through disclosures from individuals and multiple sources. Targets include methyltransferases, demethylases and ubiquitin-related enzymes. Importantly, each programme benefits from ongoing input from the leading researchers in the field.
The company also has generated a series of research tools as well as epigenetic-related screens and markers that cover cellular reprogramming and induced pluripotency. CellCentric was founded in 2004 with Prof Azim Surani FRS, University of Cambridge.
|
